| Name | Title | Contact Details |
|---|
Life Spine is a Hoffman Estates, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DJO Global is a leading global developer, manufacturer and distributor of high-quality medical devices that provide solutions for musculoskeletal health, vascular health and pain management. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Our products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of our medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. Product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. Our surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. Our products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, Exos™, Dr. Comfort®, DonJoy Performance® and DJO® Surgical. DJO is headquartered in Vista, CA and is a portfolio company of the Blackstone Group.
NuVasive® is an innovative medical device company focused on developing minimally disruptive surgical products and procedures for the spine. Our mission is to improve the lives of patients who suffer from debilitating back, neck, or leg pain by creating cutting-edge products and procedures that revolutionize spine surgery through focusing on Speed of Innovation®, Absolute Responsiveness®, and Superior Clinical Results. Through innovative technological advancements, NuVasive has successfully progressed major spine surgery to where many patients have experienced extraordinary results—they are often walking the same day of surgery, experiencing less blood loss, spending less time in the hospital, and going back to work within four to six weeks (versus six months). NuVasive is the third largest medical device company in the global spine industry. We feature more than 90 products spanning lumbar, thoracic, and cervical applications, neuromonitoring services, and a biologics portfolio. Our products have been used in hundreds of thousands of spine surgeries. NuVasive had revenues of $811 million in 2015, including sales in over 30 countries, and employs more than 1,600 people globally. Corporate headquarters are in San Diego, California and Amsterdam, the Netherlands serves as international headquarters. The company has additional offices in the U.S. located in the states of Tennessee, Ohio, Maryland, and California. Internationally, NuVasive has additional offices located Puerto Rico, the United Kingdom, Germany, Italy, Australia, Spain, Singapore, and Japan.
Claghorn-Lesem Research Clinic is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.